FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3198155674> ?p ?o ?g. }

• W3198155674 endingPage "S1156.e1" @default.
• W3198155674 startingPage "S1145" @default.
• W3198155674 abstract "Patients at high risk of severe preeclampsia and fetal growth restriction have low circulating levels of placental growth factor and features of maternal vascular malperfusion placental pathology at delivery. Multimodal screening and commencement of aspirin prophylaxis at 11 to 13 weeks' gestation markedly reduces the risk of preterm delivery with preeclampsia. However, the additional role of low-molecular-weight heparin and mechanisms of action remain uncertain. Because low-molecular-weight heparin augments the production and release of placental growth factor in vitro by both placental villi and vascular endothelium, it may be effective to suppress the risk of severe preeclampsia in a niche group of high-risk patients with low circulating placental growth factor in the early second trimester.This study aimed to define a gestational age-specific reference range for placental growth factor and to test the hypothesis that prophylactic low-molecular-weight heparin administered in the early second trimester may restore deficient circulating placental growth factor levels and thereby prolong pregnancy.Centile curves for circulating placental growth factor levels from 12 to 36 weeks' gestation were derived using quantile regression of combined data from a published cohort of 4207 unselected nulliparous patients in Cambridge, United Kingdom, at 4 sampling time points (12, 20, 28, and 36 weeks' gestation) and the White majority (n=531) of a healthy nulliparous cohort in Toronto, Canada, at 16 weeks' gestation using the same test platform. Within a specialty high-risk clinic in Toronto, a niche group of 7 patients with a circulating placental growth factor at the <10th centile in the early second trimester received daily prophylactic low-molecular-weight heparin (enoxaparin; 40 mg subcutaneously) and were followed up until delivery (group 1). Their baseline characteristics, delivery details, and placental pathologies were compared with 5 similar patients who did not receive low-molecular-weight heparin during the observation period (group 2) and further with 21 patients who delivered with severe preeclampsia (group 3) in the same institution.A gestational age-specific reference range for placental growth factor levels at weekly intervals between 12 and 36 weeks was established for White women with singleton pregnancies. Within group 1, 5 of 7 patients demonstrated a sustained increase in circulating placental growth factor levels, whereas placental growth factor levels did not increase in group 2 or group 3 patients who did not receive low-molecular-weight heparin. Group 1 patients receiving low-molecular-weight heparin therapy exhibited a later gestation at delivery, relative to groups 2 and 3 (36 weeks [33-37] vs 23 weeks [22-26] and 28 weeks [27-31], respectively), and consequently had higher birthweights (1.93 kg [1.1-2.7] vs 0.32 kg [0.19-0.39] and 0.73 kg [0.52-1.03], respectively). The incidence of stillbirth was lowest in group 1 (14% [1 of 7]), relative to groups 2 and 3 (80% [4 of 5] and 29% [6 of 21], respectively). Maternal vascular malperfusion was the most common placental pathology found in association with abnormal uterine artery Doppler.In patients at high risk of a serious adverse pregnancy outcome owing to placental disease, the addition of low-molecular-weight heparin to aspirin prophylaxis in the early second trimester may restore deficient circulating placental growth factor to mediate an improved perinatal outcome. These data support the implementation of a multicenter pilot randomized control trial where patients are recruited primarily based on the assessment of placental function in the early second trimester." @default.
• W3198155674 created "2021-09-13" @default.
• W3198155674 creator A5000898704 @default.
• W3198155674 creator A5030287465 @default.
• W3198155674 creator A5032930756 @default.
• W3198155674 creator A5034333560 @default.
• W3198155674 creator A5039169591 @default.
• W3198155674 creator A5041711562 @default.
• W3198155674 creator A5047122287 @default.
• W3198155674 creator A5052639315 @default.
• W3198155674 creator A5087745826 @default.
• W3198155674 creator A5091517073 @default.
• W3198155674 date "2022-02-01" @default.
• W3198155674 modified "2023-10-16" @default.
• W3198155674 title "Circulating maternal placental growth factor responses to low-molecular-weight heparin in pregnant patients at risk of placental dysfunction" @default.
• W3198155674 cites W1516891673 @default.
• W3198155674 cites W1808045199 @default.
• W3198155674 cites W1987646940 @default.
• W3198155674 cites W2006245385 @default.
• W3198155674 cites W2006555017 @default.
• W3198155674 cites W2010437981 @default.
• W3198155674 cites W2011780571 @default.
• W3198155674 cites W2012238028 @default.
• W3198155674 cites W2019033274 @default.
• W3198155674 cites W2069029007 @default.
• W3198155674 cites W2073599064 @default.
• W3198155674 cites W2074367236 @default.
• W3198155674 cites W2081876722 @default.
• W3198155674 cites W2085996860 @default.
• W3198155674 cites W2091453765 @default.
• W3198155674 cites W2092592525 @default.
• W3198155674 cites W2136326182 @default.
• W3198155674 cites W2139870988 @default.
• W3198155674 cites W2154065358 @default.
• W3198155674 cites W2170867031 @default.
• W3198155674 cites W2233120868 @default.
• W3198155674 cites W2250497524 @default.
• W3198155674 cites W2260113709 @default.
• W3198155674 cites W2267669237 @default.
• W3198155674 cites W2305634705 @default.
• W3198155674 cites W2319251802 @default.
• W3198155674 cites W2399942170 @default.
• W3198155674 cites W2531818013 @default.
• W3198155674 cites W2539366050 @default.
• W3198155674 cites W2553380648 @default.
• W3198155674 cites W2580083952 @default.
• W3198155674 cites W2604986744 @default.
• W3198155674 cites W2730504020 @default.
• W3198155674 cites W2734414153 @default.
• W3198155674 cites W2745284508 @default.
• W3198155674 cites W2763267980 @default.
• W3198155674 cites W2771766527 @default.
• W3198155674 cites W2772314736 @default.
• W3198155674 cites W2775090827 @default.
• W3198155674 cites W2803674488 @default.
• W3198155674 cites W2807066099 @default.
• W3198155674 cites W2900398263 @default.
• W3198155674 cites W2906320430 @default.
• W3198155674 cites W2973592823 @default.
• W3198155674 cites W2996405986 @default.
• W3198155674 cites W3010880466 @default.
• W3198155674 cites W3020359021 @default.
• W3198155674 cites W3039401173 @default.
• W3198155674 cites W3112552530 @default.
• W3198155674 cites W3155270090 @default.
• W3198155674 cites W4251118184 @default.
• W3198155674 cites W4324262985 @default.
• W3198155674 doi "https://doi.org/10.1016/j.ajog.2021.08.027" @default.
• W3198155674 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34461078" @default.
• W3198155674 hasPublicationYear "2022" @default.
• W3198155674 type Work @default.
• W3198155674 sameAs 3198155674 @default.
• W3198155674 citedByCount "12" @default.
• W3198155674 countsByYear W31981556742022 @default.
• W3198155674 countsByYear W31981556742023 @default.
• W3198155674 crossrefType "journal-article" @default.
• W3198155674 hasAuthorship W3198155674A5000898704 @default.
• W3198155674 hasAuthorship W3198155674A5030287465 @default.
• W3198155674 hasAuthorship W3198155674A5032930756 @default.
• W3198155674 hasAuthorship W3198155674A5034333560 @default.
• W3198155674 hasAuthorship W3198155674A5039169591 @default.
• W3198155674 hasAuthorship W3198155674A5041711562 @default.
• W3198155674 hasAuthorship W3198155674A5047122287 @default.
• W3198155674 hasAuthorship W3198155674A5052639315 @default.
• W3198155674 hasAuthorship W3198155674A5087745826 @default.
• W3198155674 hasAuthorship W3198155674A5091517073 @default.
• W3198155674 hasBestOaLocation W31981556741 @default.
• W3198155674 hasConcept C126322002 @default.
• W3198155674 hasConcept C131872663 @default.
• W3198155674 hasConcept C167734588 @default.
• W3198155674 hasConcept C172680121 @default.
• W3198155674 hasConcept C2776871010 @default.
• W3198155674 hasConcept C2776884760 @default.
• W3198155674 hasConcept C2776953305 @default.
• W3198155674 hasConcept C2777025900 @default.
• W3198155674 hasConcept C2777218350 @default.
• W3198155674 hasConcept C2777557582 @default.
• W3198155674 hasConcept C2778376644 @default.

• next